Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGCT 2021 | TCR gene editing in cancer therapy

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes the rationale behind the use of T-cell receptor (TCR) gene editing to improve adoptive T cell therapy for cancer. While chimeric antigen receptors (CAR) T-cell therapy can be a useful approach when targeting antigens present on the cancer cell surface, TCR therapy is often employed when targeting intracellular tumor antigens. Dr Bonini explains how TCR gene editing can allow better control of the level of expression, efficacy and safety profile of TCR therapy. This interview took place at the European Society of Gene & Cell Therapy (ESGCT) Virtual Congress 2021.